Dirithromycin

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Dirithromycin

Articles

Most recent articles on Dirithromycin

Most cited articles on Dirithromycin

Review articles on Dirithromycin

Articles on Dirithromycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dirithromycin

Images of Dirithromycin

Photos of Dirithromycin

Podcasts & MP3s on Dirithromycin

Videos on Dirithromycin

Evidence Based Medicine

Cochrane Collaboration on Dirithromycin

Bandolier on Dirithromycin

TRIP on Dirithromycin

Clinical Trials

Ongoing Trials on Dirithromycin at Clinical Trials.gov

Trial results on Dirithromycin

Clinical Trials on Dirithromycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dirithromycin

NICE Guidance on Dirithromycin

NHS PRODIGY Guidance

FDA on Dirithromycin

CDC on Dirithromycin

Books

Books on Dirithromycin

News

Dirithromycin in the news

Be alerted to news on Dirithromycin

News trends on Dirithromycin

Commentary

Blogs on Dirithromycin

Definitions

Definitions of Dirithromycin

Patient Resources / Community

Patient resources on Dirithromycin

Discussion groups on Dirithromycin

Patient Handouts on Dirithromycin

Directions to Hospitals Treating Dirithromycin

Risk calculators and risk factors for Dirithromycin

Healthcare Provider Resources

Symptoms of Dirithromycin

Causes & Risk Factors for Dirithromycin

Diagnostic studies for Dirithromycin

Treatment of Dirithromycin

Continuing Medical Education (CME)

CME Programs on Dirithromycin

International

Dirithromycin en Espanol

Dirithromycin en Francais

Business

Dirithromycin in the Marketplace

Patents on Dirithromycin

Experimental / Informatics

List of terms related to Dirithromycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dirithromycin is a macrolide glycopeptide antibiotic. Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine ring thus formed is a hemi-aminal that is unstable under both acidic and alkaline aqueous conditions and undergoes spontaneous hydrolysis to form erythromycyclamine. Erythromycyclamine is a semisynthetic derivative of erythromycin in which the 9-ketogroup of the erythronolide ring has been converted to an amino group. Erythromycyclamine retains the antibacterial properties of erythromycin oral administration. The prodrug, dirithromycin, is provided as enteric coated tablets to protect it from acid catalyzed hydrolysis in the stomach. Orally administered dirithromycin is absorbed rapidly into the plasma, largely from the small intestine. Spontaneous hydrolysis to erythromycyclamine occurs in the plasma. Oral bioavailability is estimated to be about 10%, but food does not affect absorption of the prodrug.

Discontinuation

Dirithromycin is no longer available in the United States.[1] Since the production of dirithromycin is discontinued in the U.S, National Institutes of Health recommend that people taking dirithromycin should consult their physicians to discuss switching to another treatment.[2] However, dirithromycin is still available in many european countries.

References

  1. "Dynabac Drug Details". U.S. Food and Drug Administration. Retrieved 2007-05-25.
  2. "Dirithromycin". MedlinePlus. U.S. National Library of Medicine. January 1, 2006. Archived from the original on 2007-03-29. Retrieved 2007-05-25.

Linked-in.jpg